Loading...
01/11 16:20
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
Revenue $1.4 billion, with a 3.1% underlying growth and 1.6% reported after a 150 basis points headwind from foreign exchange. The growth includes the effect of 1 fewer trading day than in Q1 2024, which proportionately reduced growth by around 1.7 percentage points.
U.S. Revenue Growth 3.6% growth in the U.S. market, with a 5% growth in other established markets. The decline in emerging markets was 1.7%, primarily due to headwinds in China.
Orthopaedics Growth 3.2% growth in Orthopaedics, with 5.1% growth excluding China. The growth reflects a change in reporting practices around robotics.
Trauma & Extremities Growth 6.3% growth, driven by the EVOS Plating System and the AETOS Shoulder.
Advanced Wound Management Growth 3.8% growth, with Advanced Wound Care growing 2.5% and Advanced Wound Devices growing 15.7%, mainly driven by Negative Pressure Wound Therapy.
Tariff Impact Expected net impact of around $15 million to $20 million from recently announced tariffs, which the company expects to absorb within existing margin guidance.
New Product Launches: ALLEVYN Ag+ SURGICAL is in the early stages of its U.S. launch, adding a new antimicrobial dressing to our foams portfolio.
Product Portfolio Expansion: Further developed cementless knee offering with the addition of LEGION Medial Stablized Inserts, which received 510(k) clearance.
Clinical Evidence: REGENETEN showed a highly statistically significant reduction in the re-tear rate with a 65% lower relative risk compared to repair alone.
Market Growth: Achieved 3.1% underlying revenue growth in Q1 2025, with 3.6% growth in the U.S. and 5% in other established markets.
Emerging Markets Performance: 1.7% decline in emerging markets due to headwinds in China, which are believed to have peaked.
Operational Improvements: Building on the operational and commercial improvements of the 12-Point Plan, leading to better product availability and commercial execution.
Cost Savings Impact: Expect to absorb the impact of recently announced tariffs within existing margin guidance, with a net impact of around $15 million to $20 million.
Strategic Focus: Continued focus on innovation-driven growth across key platforms, including Orthopaedics and Advanced Wound Management.
Market Positioning: Maintaining full year guidance on revenue growth and trading margin despite external challenges.
China Market Headwinds: The company faced a 240 basis points headwind in China, which has now peaked, but it contributed to a 1.7% decline in emerging markets.
Tariffs Impact: The recently announced tariffs are expected to have a net impact of around $15 million to $20 million, which the company anticipates absorbing within its existing margin guidance.
Foreign Exchange Headwinds: The reported revenue growth was affected by a 150 basis points headwind from foreign exchange.
Supply Chain Challenges: The company is working to mitigate tariffs on products and raw materials imported into the U.S. and is leveraging its global manufacturing network to address supply chain issues.
Trading Day Effect: The company experienced a reduction in growth due to having one fewer trading day compared to the previous year, which is estimated to have reduced growth by around 1.7 percentage points.
12-Point Plan: Operational and commercial improvements have been made, leading to better product availability and commercial execution.
Innovation-Driven Growth: Key platforms such as CORI, EVOS, REGENETEN, and Negative Pressure Wound Therapy are driving strong double-digit growth.
New Product Launches: Expanding offerings in high-growth categories including foams dressings and cementless knees.
Clinical Evidence: New data supporting OXINIUM and rotator cuff repair to enhance product adoption.
Revenue Growth Guidance: Full year guidance remains unchanged with expectations for higher growth in the remaining 9 months.
Impact of Tariffs: Expected net impact of tariffs is around $15 million to $20 million, which will be absorbed within existing margin guidance.
Q1 Revenue: Revenue for Q1 was $1.4 billion with a 3.1% underlying growth.
Trading Margin: Trading margin guidance remains unchanged for the full year.
Share Buyback Program: None
The earnings call summary presents a mixed outlook: strong product innovation and market strategy are offset by uncertainties in tariffs and CMS proposals. The Q&A session reveals management's cautious optimism, but with some unclear responses. Financial performance and guidance remain stable, yet the lack of clear answers on certain risks tempers enthusiasm. Given these factors, a neutral rating is appropriate as the stock may not significantly change over the next two weeks.
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
The earnings call reflects mixed signals: Financial performance shows growth but is hampered by challenges in China, affecting margins and revenue outlook. The Q&A highlights uncertainties about recovery in key markets and competitive pressures. Despite some positive developments in product feedback and growth outside China, the lack of share buybacks and flat dividend policy suggest cautious financial health management. Overall, the market reaction is likely neutral, balancing growth prospects with significant regional headwinds and strategic uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
